Edgar Filing: eXegenics Inc

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

HSIAO JANE PH D

2. Issuer Name and Ticker or Trading Symbol
eXegenics Inc [EXEG]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

(Last)

(First)

(Middle)

4400 BISCAYNE BOULEVARD, 15TH FLOOR

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2007

(Street)

MIAMI, FL 33137

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/27/2007		A		11,604,144	A	⁽¹⁾	4,095,581	D
Common Stock								15,490,546	I	See Footnote ⁽²⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Warrants (Right to Buy)

$ 0.6728

03/27/2007

978,860

⁽³⁾

03/27/2017

Common Stock

978,860

⁽¹⁾

345,480

Warrants (Right to Buy)

$ 0.8473

03/27/2007

978,860

⁽³⁾

03/27/2017

Common Stock

978,860

⁽¹⁾

345,480

Warrants (Right to Buy)

$ 1.0466

03/27/2007

978,860

⁽³⁾

03/27/2017

Common Stock

978,860

⁽¹⁾

345,480

Warrants (Right to Buy)

$ 0.4984

03/27/2007

4,000,000

⁽³⁾

03/27/2017

Common Stock

4,000,000

⁽⁴⁾

4,000,000

See Footnote ⁽²⁾

Warrants (Right to Buy)

$ 0.0002

03/27/2007

81,085

⁽³⁾

01/11/2017

Common Stock

81,085

⁽⁵⁾

81,085

See Footnote ⁽²⁾

Warrants (Right to Buy)

$ 38.54

03/27/2007

6,487

⁽³⁾

01/11/2017

Common Stock

648,700

⁽⁵⁾

6,487

See Footnote ⁽²⁾

Warrants (Right to Buy)

$ 0.672

03/27/2007

22,124

⁽³⁾

03/27/2017

Common Stock

22,124

⁽⁵⁾

22,124

See Footnote ⁽²⁾

Warrants (Right to Buy)

$ 0.8473

03/27/2007

22,124

⁽³⁾

03/27/2017

Common Stock

22,124

⁽⁵⁾

22,124

See Footnote ⁽²⁾

Warrants (Right to Buy)

$ 1.0467

03/27/2007

22,125

⁽³⁾

03/27/2017

Common Stock

22,125

⁽⁵⁾

22,125

See Footnote ⁽²⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
HSIAO JANE PH D 4400 BISCAYNE BOULEVARD 15TH FLOOR MIAMI, FL 33137	X

Signatures

/s/ Jane Hsiao, Ph.D		03/29/2007
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The reporting person acquired these securities in connection with the merger of Froptix Corporation into a wholly-owned subsidiary of the issuer in exchange for securities of Froptix held by the reporting person immediately before the merger. On the effective date of the merger the closing sales price of the issuer's common stock was $3.28.
(2)	These securities are owned directly by The Frost Group, LLC. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
(3)	These warrants are immediately exercisable.
(4)	These warrants were acquired by The Frost Group as part of the consideration paid by the issuer for a line of credit extended by The Frost Group to the issuer in connection with the merger.
(5)	The Frost Group acquired these securities in connection with the merger of Acuity Pharmaceuticals, Inc. into a wholly-owned subsidiary of the issuer in exchange for securities of Acuity held by The Frost Group immediately before the merger. On the effective date of the merger the closing sales price of the issuer's common stock was $3.28 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.